A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose Range Finding Study to Evaluate the Safety, Hemodynamic Effects and Efficacy of Intramuscular Injection of Human Placenta-derived Cells (Pda-002) in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease

Trial Profile

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose Range Finding Study to Evaluate the Safety, Hemodynamic Effects and Efficacy of Intramuscular Injection of Human Placenta-derived Cells (Pda-002) in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 26 Apr 2016

At a glance

  • Drugs PDA 002 (Primary)
  • Indications Diabetic foot ulcer; Peripheral arterial disorders
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 20 Apr 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Sep 2017.
    • 20 Apr 2016 Status changed from active, no longer recruiting to withdrawn prior to enrolment due to significant delays in the expected availability of data.
    • 04 Jan 2016 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top